Answers are grounded in this paper and cite their sources.
Objective: Evidence on multiple myeloma (MM) in the real-world settings (RWS) is scarce.Our study describes patient characteristics, treatment patterns, the overall response rate (ORR), overall survival (OS), and time to next treatment line (TTNT) in MM patients in RWS in Finland.Materials and methods: This observational cohort study included patients with MM who were ≥18 years of age from the Finnish Hematology Registry.The patients from Helsinki and Uusimaa districts had been diagnosed with MM during 2010-2015 and followed up until 2017.Results: This study included 224 patients with a median age of 67.7 years.Of note, 60% of the patients <70 years of age had received autologous hematological stem-cell transplantation (HSCT), while no patient ≥70 years of age had been treated with HSCT.For first-line treatment, the ORR was 81.9%, the median TTNT 8.5 months, and the median duration of treatment 3.2 months.Median OS was 62.4 months for all patients and 48.2 months for patients with high-risk cytogenetics [del(17p), t(4;14), t(4;16), t(4;20)].Conclusion: This study reflects myeloma treatment practice in Finland in the era when bortezomib and lenalidomide were still regarded as "novel" treatments.Although first-line TTNT was short, the OS was comparable with other RWS studies.This reflects the need to change the firstline treatment due to both toxicity and the suboptimal response seen in real-world practice.Further, the shorter OS among patients with high-risk cytogenetics highlights the need for identifying such patients and improving their treatment paradigms as early as possible.
No takes yet. Share an insight, caveat, or question.
Giorgi Tskhvarashvili (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: